Abiopharma

🔍 Collins Helen Louise (Executive)

Company: Enliven Therapeutics, Inc. (ELVN)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $2.48 per share (Direct)
  Date: 2026-03-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,000 shares of Common Stock at $27.76 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4
• Sold 5,000 shares of Stock Option (right to buy) at $2.48 per share (Derivative)
  Date: 2026-03-17 | Code: M | Expires: 2031-06-17 | equity_swap_involved: 0 | shares_owned_after: 176,268.00 | transaction_form_type: 4 | Footnotes: F1, F5

Footnotes:

• F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
• F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F3: This transaction was executed in multiple trades at prices ranging from $27.40 to $28.2278. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F4: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• F5: All of the shares subject to this option are fully vested and exercisable as of the date hereof.